Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Biotechnology

Healthcare
$9.13 +0.66%

+$0.13 today

Market cap
$821.96M
Beta
0.39
P/E (TTM)
-6.8
EPS (TTM)
-$2.81
52W Low $8.59High $25.59

Volume 3.30M

Average 1.70M

Income Statement

Follow revenue through to earnings.

Revenue

$172.35M

FY 2025 · Annual

+627.8% YoY

Operating Income

-$273.08M

FY 2025 · Annual

Net Income

-$285.42M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue139.71M0023.68M172.35M
Cost of Revenue000826K6.97M
Gross Profit139.71M0022.85M165.38M
Gross Margin100.0%——96.5%96.0%
Research & Development88.25M118.5M163.03M241.65M258.78M
Selling, General & Admin25.24M33.26M66.92M120.88M179.68M
Operating Expenses113.49M151.76M229.95M362.53M438.47M
Depreciation & Amortization43K33K12K8K6K
EBITDA26.87M(146.17M)(209.14M)(313.82M)(251.63M)
EBITDA Margin19.2%——-1325.3%-146.0%
Operating Income26.22M(151.76M)(229.95M)(339.67M)(273.08M)
Operating Margin18.8%——-1434.4%-158.4%
Interest Income403K5.87M21.16M26.09M22.73M
Interest Expense1.9M3.14M208K4.93M33.79M
Other Income / Expenses(1.29M)2.42M20.59M20.91M(12.34M)
Income Before Tax24.93M(149.34M)(209.36M)(318.76M)(285.42M)
Pre-Tax Margin17.8%——-1346.1%-165.6%
Income Tax Expense00000
Net Income24.93M(149.34M)(209.36M)(318.76M)(285.42M)
Net Margin17.8%——-1346.1%-165.6%
EPS (Basic)0.48(2.46)(2.98)(3.73)(3.29)
EPS (Diluted)0.48(2.46)(2.98)(3.73)(3.29)
Weighted Avg Shares52.06M60.76M70.37M85.62M86.63M
Weighted Avg Shares (Diluted)52.06M60.76M70.37M85.62M86.63M

SNDX Earnings Waterfall · TTM

NASDAQ:SNDX · Revenue to Net Income

Key Ratios

EPS$-2.80
Gross Margin97.6%
Net Margin-121.7%
P/E Ratio-6.7
P/S Ratio27.0

Analysis

$217.2M of revenue converted into -$243.2M of net income for the selected period. Gross margin is 97.6% and net margin is -121.7%, showing how much revenue survives after costs and taxes. EPS is $-2.80, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
3Initial statement of beneficial ownershipNov 12, 2026
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 2, 2026
8-KCurrent reportNov 2, 2026

How much revenue does SNDX generate?

Syndax Pharmaceuticals, Inc. (SNDX) reported $172.35M of revenue in fiscal 2025.

Is SNDX profitable?

Syndax Pharmaceuticals, Inc. (SNDX) reported -$285.42M of net income, with a net margin of -165.6%.